Journal of Hematology & Oncology

Papers
(The TQCC of Journal of Hematology & Oncology is 50. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2020-04-01 to 2024-04-01.)
ArticleCitations
Ferroptosis, necroptosis, and pyroptosis in anticancer immunity674
Targeting the Wnt/β-catenin signaling pathway in cancer621
SARS-CoV-2 binds platelet ACE2 to enhance thrombosis in COVID-19478
Nanomaterials for cancer therapy: current progress and perspectives466
EZH2: a novel target for cancer treatment438
Tumor-derived exosomal miR-934 induces macrophage M2 polarization to promote liver metastasis of colorectal cancer357
NK cell-based cancer immunotherapy: from basic biology to clinical development305
Next generation of immune checkpoint inhibitors and beyond294
Regulation of PD-L1 expression in the tumor microenvironment277
Roles of METTL3 in cancer: mechanisms and therapeutic targeting264
cGAS-STING, an important pathway in cancer immunotherapy250
Challenges and advances in clinical applications of mesenchymal stromal cells247
Tyrosine kinase inhibitors for solid tumors in the past 20 years (2001–2020)226
RNA sequencing: new technologies and applications in cancer research226
Cancer vaccines as promising immuno-therapeutics: platforms and current progress225
The MAPK and AMPK signalings: interplay and implication in targeted cancer therapy223
Isolation and characterization of exosomes for cancer research209
Combination strategies to maximize the benefits of cancer immunotherapy206
Dendritic cell biology and its role in tumor immunotherapy203
Proteolysis-targeting chimera (PROTAC) for targeted protein degradation and cancer therapy196
Immunosenescence: a key player in cancer development195
Targeting mutant p53 for cancer therapy: direct and indirect strategies193
Targeting hypoxic tumor microenvironment in pancreatic cancer192
Novel therapies emerging in oncology to target the TGF-β pathway191
Recent advances in CAR-T cell engineering190
Neutrophils in cancer carcinogenesis and metastasis189
Emerging role of exosomes in cancer progression and tumor microenvironment remodeling182
Bispecific CAR-T cells targeting both CD19 and CD22 for therapy of adults with relapsed or refractory B cell acute lymphoblastic leukemia178
Identification of a small molecule as inducer of ferroptosis and apoptosis through ubiquitination of GPX4 in triple negative breast cancer cells177
Applications of single-cell sequencing in cancer research: progress and perspectives177
COVID-19 infection in adult patients with hematological malignancies: a European Hematology Association Survey (EPICOVIDEHA)174
Spatial architecture of the immune microenvironment orchestrates tumor immunity and therapeutic response174
Pluripotent stem cell-derived CAR-macrophage cells with antigen-dependent anti-cancer cell functions170
The molecular mechanisms and therapeutic strategies of EMT in tumor progression and metastasis167
m6A-binding proteins: the emerging crucial performers in epigenetics166
Liquid biopsy: current technology and clinical applications164
Molecular alterations and targeted therapy in pancreatic ductal adenocarcinoma161
Oncolytic viruses for cancer immunotherapy158
Recent advances in therapeutic strategies for triple-negative breast cancer157
Emerging therapeutic agents for advanced non-small cell lung cancer156
Indoleamine 2,3-dioxygenase 1 (IDO1) inhibitors in clinical trials for cancer immunotherapy155
Impact of hematologic malignancy and type of cancer therapy on COVID-19 severity and mortality: lessons from a large population-based registry study154
RNA-binding proteins in tumor progression150
Targeting CD47 for cancer immunotherapy147
Targeting cell death pathways for cancer therapy: recent developments in necroptosis, pyroptosis, ferroptosis, and cuproptosis research145
Burden of anemia and its underlying causes in 204 countries and territories, 1990–2019: results from the Global Burden of Disease Study 2019142
Targeting MCL-1 in cancer: current status and perspectives142
Fifth-week immunogenicity and safety of anti-SARS-CoV-2 BNT162b2 vaccine in patients with multiple myeloma and myeloproliferative malignancies on active treatment: preliminary data from a single insti142
HMGB1 released from GSDME-mediated pyroptotic epithelial cells participates in the tumorigenesis of colitis-associated colorectal cancer through the ERK1/2 pathway140
Improvement of the anticancer efficacy of PD-1/PD-L1 blockade via combination therapy and PD-L1 regulation139
Next-generation immuno-oncology agents: current momentum shifts in cancer immunotherapy136
Chimeric antigen receptor natural killer (CAR-NK) cell design and engineering for cancer therapy133
Therapeutic roles of mesenchymal stem cell-derived extracellular vesicles in cancer132
MEK inhibitors for the treatment of non-small cell lung cancer132
Immunosuppressive cells in cancer: mechanisms and potential therapeutic targets127
A WEE1 family business: regulation of mitosis, cancer progression, and therapeutic target126
Cancer stem cell secretome in the tumor microenvironment: a key point for an effective personalized cancer treatment125
Antibody–drug conjugates in solid tumors: a look into novel targets125
Targeted therapy in advanced non-small cell lung cancer: current advances and future trends125
Cancer history is an independent risk factor for mortality in hospitalized COVID-19 patients: a propensity score-matched analysis124
Gut microbiota influence immunotherapy responses: mechanisms and therapeutic strategies123
Global, regional, and national cancer incidence and death for 29 cancer groups in 2019 and trends analysis of the global cancer burden, 1990–2019122
Targeting extracellular matrix stiffness and mechanotransducers to improve cancer therapy122
The consensus from The Chinese Society of Hematology on indications, conditioning regimens and donor selection for allogeneic hematopoietic stem cell transplantation: 2021 update121
VISTA: an immune regulatory protein checking tumor and immune cells in cancer immunotherapy119
HMGB1 in inflammation and cancer117
Modeling neoplastic disease with spheroids and organoids117
Hypoxia-inducible factors: master regulators of hypoxic tumor immune escape116
Chimeric antigen receptor-engineered natural killer cells for cancer immunotherapy114
The construction, expression, and enhanced anti-tumor activity of YM101: a bispecific antibody simultaneously targeting TGF-β and PD-L1114
XPO1-dependent nuclear export as a target for cancer therapy114
The global burden and attributable risk factor analysis of acute myeloid leukemia in 195 countries and territories from 1990 to 2017: estimates based on the global burden of disease study 2017110
Emerging agents that target signaling pathways in cancer stem cells109
Bispecific T cell engagers: an emerging therapy for management of hematologic malignancies109
Insulin-like growth factor receptor signaling in tumorigenesis and drug resistance: a challenge for cancer therapy106
Targeting autophagy to overcome drug resistance: further developments106
Exploring immunotherapy in colorectal cancer105
tRNA-derived RNA fragments in cancer: current status and future perspectives105
BCMA-targeted immunotherapy for multiple myeloma105
IL-7 and CCL19-secreting CAR-T cell therapy for tumors with positive glypican-3 or mesothelin104
How to select IgG subclasses in developing anti-tumor therapeutic antibodies103
The management of metastatic GIST: current standard and investigational therapeutics102
N6-methyladenosine methyltransferases: functions, regulation, and clinical potential100
The impact of the temporary suspension of national cancer screening programmes due to the COVID-19 epidemic on the diagnosis of breast and colorectal cancer in the Netherlands100
Emerging agents and regimens for AML99
Role of lysosomes in physiological activities, diseases, and therapy99
Mesenchymal stem/stromal cells in cancer therapy98
High mobility group box 1 (HMGB1): a pivotal regulator of hematopoietic malignancies98
Evolving therapy of adult acute lymphoblastic leukemia: state-of-the-art treatment and future directions97
Advances in synthetic lethality for cancer therapy: cellular mechanism and clinical translation96
Expression patterns of immune checkpoints in acute myeloid leukemia95
A tertiary center experience of multiple myeloma patients with COVID-19: lessons learned and the path forward94
Enhancing the therapeutic efficacy of nanoparticles for cancer treatment using versatile targeted strategies94
The potential role of N7-methylguanosine (m7G) in cancer93
Gene modification strategies for next-generation CAR T cells against solid cancers92
Targeting Akt in cancer for precision therapy92
Emerging strategies to target RAS signaling in human cancer therapy91
Postoperative circulating tumor DNA as markers of recurrence risk in stages II to III colorectal cancer90
Genetic alteration, RNA expression, and DNA methylation profiling of coronavirus disease 2019 (COVID-19) receptor ACE2 in malignancies: a pan-cancer analysis89
The application and prospect of CDK4/6 inhibitors in malignant solid tumors88
MCL-1 inhibitors, fast-lane development of a new class of anti-cancer agents88
Immune checkpoint modulators in cancer immunotherapy: recent advances and emerging concepts88
Targeting EphA2 in cancer87
Safety and clinical efficacy of BCMA CAR-T-cell therapy in multiple myeloma87
The long and short non-coding RNAs modulating EZH2 signaling in cancer87
A bispecific CAR-T cell therapy targeting BCMA and CD38 in relapsed or refractory multiple myeloma86
YTHDF2 facilitates UBXN1 mRNA decay by recognizing METTL3-mediated m6A modification to activate NF-κB and promote the malignant progression of glioma84
LCAT3, a novel m6A-regulated long non-coding RNA, plays an oncogenic role in lung cancer via binding with FUBP1 to activate c-MYC82
Treatment of relapsed/refractory chronic lymphocytic leukemia/small lymphocytic lymphoma with the BTK inhibitor zanubrutinib: phase 2, single-arm, multicenter study81
The relationship between expression of PD-L1 and HIF-1α in glioma cells under hypoxia81
Contradictory roles of lipid metabolism in immune response within the tumor microenvironment81
Reactive cutaneous capillary endothelial proliferation in advanced hepatocellular carcinoma patients treated with camrelizumab: data derived from a multicenter phase 2 trial80
COVID-19 vaccines for patients with cancer: benefits likely outweigh risks79
HLF regulates ferroptosis, development and chemoresistance of triple-negative breast cancer by activating tumor cell-macrophage crosstalk78
A novel lncRNA ROPM-mediated lipid metabolism governs breast cancer stem cell properties77
Novel therapies are changing treatment paradigms in metastatic prostate cancer76
A randomized, open-label, Phase III study of obinutuzumab or rituximab plus CHOP in patients with previously untreated diffuse large B-Cell lymphoma: final analysis of GOYA76
Role of CD47 in Hematological Malignancies75
New agents and regimens for diffuse large B cell lymphoma73
MYC: a multipurpose oncogene with prognostic and therapeutic implications in blood malignancies73
HNRNPA2B1 promotes multiple myeloma progression by increasing AKT3 expression via m6A-dependent stabilization of ILF3 mRNA72
Epidemiological trends of tracheal, bronchus, and lung cancer at the global, regional, and national levels: a population-based study72
Circular RNAs: characteristics, biogenesis, mechanisms and functions in liver cancer70
Severe COVID-19 virus reactivation following treatment for B cell acute lymphoblastic leukemia70
Post-transplant cyclophosphamide after matched sibling, unrelated and haploidentical donor transplants in patients with acute myeloid leukemia: a comparative study of the ALWP EBMT69
Combine and conquer: manganese synergizing anti-TGF-β/PD-L1 bispecific antibody YM101 to overcome immunotherapy resistance in non-inflamed cancers67
Amplification of spatially isolated adenosine pathway by tumor–macrophage interaction induces anti-PD1 resistance in hepatocellular carcinoma67
SBRT combined with PD-1/PD-L1 inhibitors in NSCLC treatment: a focus on the mechanisms, advances, and future challenges67
Prostate cancer and PARP inhibitors: progress and challenges66
Crosstalks between inflammasome and autophagy in cancer66
Oct4 promotes M2 macrophage polarization through upregulation of macrophage colony-stimulating factor in lung cancer66
Gastric cancer treatment: recent progress and future perspectives65
Emerging role of RNA methyltransferase METTL3 in gastrointestinal cancer65
Targeting immune checkpoints in hematological malignancies65
CD38-directed CAR-T cell therapy: a novel immunotherapy strategy for relapsed acute myeloid leukemia after allogeneic hematopoietic stem cell transplantation65
CD155 immunoregulation as a target for natural killer cell immunotherapy in glioblastoma65
FGFR-TKI resistance in cancer: current status and perspectives64
DT2216—a Bcl-xL-specific degrader is highly active against Bcl-xL-dependent T cell lymphomas64
Proteolysis targeting chimeras (PROTACs) are emerging therapeutics for hematologic malignancies63
T-cell receptor-based therapy: an innovative therapeutic approach for solid tumors63
Development of a novel combined nomogram model integrating deep learning-pathomics, radiomics and immunoscore to predict postoperative outcome of colorectal cancer lung metastasis patients63
Small-molecule inhibitors, immune checkpoint inhibitors, and more: FDA-approved novel therapeutic drugs for solid tumors from 1991 to 202163
SARS-CoV-2 interacts with platelets and megakaryocytes via ACE2-independent mechanism61
Born to survive: how cancer cells resist CAR T cell therapy61
RNA demethylase ALKBH5 in cancer: from mechanisms to therapeutic potential60
Third-line therapy for chronic myeloid leukemia: current status and future directions60
STOML2 potentiates metastasis of hepatocellular carcinoma by promoting PINK1-mediated mitophagy and regulates sensitivity to lenvatinib60
Targeting p53–MDM2 interaction by small-molecule inhibitors: learning from MDM2 inhibitors in clinical trials60
Principles and innovative technologies for decrypting noncoding RNAs: from discovery and functional prediction to clinical application60
Warburg effect in colorectal cancer: the emerging roles in tumor microenvironment and therapeutic implications60
Mechanisms and rejuvenation strategies for aged hematopoietic stem cells59
Reshaping the systemic tumor immune environment (STIE) and tumor immune microenvironment (TIME) to enhance immunotherapy efficacy in solid tumors58
Impact of the COVID-19 pandemic on diagnosis, stage, and initial treatment of breast cancer in the Netherlands: a population-based study57
Advances in the diagnosis and treatment of sickle cell disease56
Natural killer cell-based immunotherapy for acute myeloid leukemia56
Thrombocytopenia and thrombosis in hospitalized patients with COVID-1956
N6-methyladenosine reader IMP2 stabilizes the ZFAS1/OLA1 axis and activates the Warburg effect: implication in colorectal cancer55
The emerging role of KDM5A in human cancer55
Pre-transplant MRD negativity predicts favorable outcomes of CAR-T therapy followed by haploidentical HSCT for relapsed/refractory acute lymphoblastic leukemia: a multi-center retrospective study54
Combination of oral STING agonist MSA-2 and anti-TGF-β/PD-L1 bispecific antibody YM101: a novel immune cocktail therapy for non-inflamed tumors53
Targeting Bruton tyrosine kinase using non-covalent inhibitors in B cell malignancies53
LncRNA-PACERR induces pro-tumour macrophages via interacting with miR-671-3p and m6A-reader IGF2BP2 in pancreatic ductal adenocarcinoma53
Burden, trends, and risk factors of esophageal cancer in China from 1990 to 2017: an up-to-date overview and comparison with those in Japan and South Korea53
Mitochondrial adaptation in cancer drug resistance: prevalence, mechanisms, and management53
Emerging agents and regimens for multiple myeloma52
Tumor organoids: applications in cancer modeling and potentials in precision medicine51
Metabolic profiles of regulatory T cells and their adaptations to the tumor microenvironment: implications for antitumor immunity51
CDK7 inhibitor THZ1 enhances antiPD-1 therapy efficacy via the p38α/MYC/PD-L1 signaling in non-small cell lung cancer50
Toll-like receptors and toll-like receptor-targeted immunotherapy against glioma50
Targeting B7-H3 via chimeric antigen receptor T cells and bispecific killer cell engagers augments antitumor response of cytotoxic lymphocytes50
Therapeutic strategies in RET gene rearranged non-small cell lung cancer50
Abnormally activated OPN/integrin αVβ3/FAK signalling is responsible for EGFR-TKI resistance in EGFR mutant non-small-cell lung cancer50
0.026968955993652